BioSpace News Archive

As we transition into a Phase III company, we want to take the opportunity to highlight recent progress and to outline our strategy as we pursue monetization of our promising drug candidates and hydrogen sulfide platform.

Simulations Plus, Inc., a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical, biotechnology, agrochemical, cosmetics and food industries, announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.

The global biologics safety testing market is predicted to exhibit a positive growth trajectory in the coming years, according to recently published report, titled, “Biologics Safety Testing Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 – 2025.”

A recent market study by TMR Research, titled, “Biologic Therapeutics Market – Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth and Forecast 2017–2025,” states that increasing applications of biological products to diagnose, thwart, and treat a range of diseases would promote the global market.

The bacterial conjunctivitis drug market in U.S. is extremely fragmented in nature as various players are operating in the market.

The rivalry between Sun Pharmaceuticals Ltd., Valeant Pharmaceuticals International Inc., Mylan N.V., F. Hoffmann-La Roche Ltd., and Merck & Co. Inc. characterizes the competitive landscape present in the global basal cell carcinoma treatment market, states a new research study by Transparency Market Research (TMR).

KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 12, 2020, at 4:30 p.m. ET, to discuss its corporate and financial results for the second quarter 2020. Conference Call Information: Interested participants and investors may access the conference call b

ELX-02 had previously been granted orphan medicinal product designation for the treatment of Cystic Fibrosis by the European Medicines Agency

POINT Biopharma Inc., a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, has completed a USD $20 Million Series A financing round.

- COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 - - Plan to Initiate New Clinical Study in Ulcerative Colitis in Q3 2020 - LEXINGTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced financial results for the second quarter 2020 and provided a